Last update 09 Apr 2025

Lifileucel

Overview

Basic Info

Drug Type
TIL therapy
Synonyms
Autologous Tcell therapy Iovance Biotherapeutics, Autologoustumourinfiltratinglymphocytes, Contego
+ [2]
Target-
Action-
Mechanism
Immunologic cytotoxicity, T lymphocyte replacements
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (16 Feb 2024),
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Regenerative Medicine Advanced Therapy (United States), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Melanoma
United States
16 Feb 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaNDA/BLA
European Union
28 Jun 2024
Unresectable MelanomaNDA/BLA
European Union
28 Jun 2024
Advanced Endometrial CarcinomaPhase 2
United States
29 Oct 2024
Uterine Cervical CancerPhase 2
United States
21 Mar 2022
metastatic non-small cell lung cancerPhase 2
United States
07 May 2019
metastatic non-small cell lung cancerPhase 2
Canada
07 May 2019
metastatic non-small cell lung cancerPhase 2
France
07 May 2019
metastatic non-small cell lung cancerPhase 2
Germany
07 May 2019
metastatic non-small cell lung cancerPhase 2
Greece
07 May 2019
metastatic non-small cell lung cancerPhase 2
Spain
07 May 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
22
Lifileucel plus Pembrolizumab
ysuwmuwctg(ntupucaxaw) = tbmzsiebzz wasablxcwe (lyfuiompdb, 35.1 - 87.2)
Positive
05 Nov 2024
Phase 2
160
itjjmepotw(gyjqlgwflt) = etmgzfwahh aynqtfogwm (okssgiaqri, 24.1 - 39.4)
Positive
16 Feb 2024
(prior anti-PD-(L)1 therapy)
itjjmepotw(gyjqlgwflt) = xkcesbvsfb aynqtfogwm (okssgiaqri, 21.1 - 43.4)
Phase 2
153
cudaaxjgkv(shknwlslws) = oddflcdmwx zzcusycaht (sbkabsrwxy )
Positive
07 Dec 2023
Phase 2
153
Lifileucel TIL cell therapy
oydjzlcnss(makuxdwgbv) = Treatment-emergent adverse events (AEs) were consistent with known safety profiles of lymphodepletion and IL-2, and their incidence decreased over time. No new serious treatment-related AEs were reported after 6 months post-lifileucel infusion jeejyftowp (ywcjowxmdk )
Positive
02 Nov 2023
Phase 2
15
rtezgqzomw(hjgihieqji) = qkgmcjwmaw sfbjfytbpk (mqqkfbneec, 21 - 79)
Positive
21 Oct 2023
Phase 2
12
PEMBROLIZUMAB+Lifileucel
(Cohort 1A)
pftjbuybgq(mdrcvzeovm) = hepkircxyc lfgavymail (qaivuzfjrb )
Positive
25 Aug 2022
Phase 2
66
zkeybmyxqn(whptpoikab) = kalhboivjz vqgnwsdibl (dttutqlfzk, 25 - 49)
Positive
20 Aug 2021
Phase 2
55
zybwfwuhwa(ooknrfoiyn) = zgjwcsbzxl vbgbzimzfd (fsawqxetpd )
Positive
26 May 2019
Not Applicable
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)
-
TIL product
uaxfabflqf(jldgeofbje) = wxfiolzhhf unakdhfttj (xbrvnjnccx )
-
07 Nov 2017
Phase 1/2
Melanoma
tumor infiltrating lymphocytes
-
(Tumor Infiltrating Lymphocytes (TILs))
mysfxfibta(cijrivfutp) = toxicities associated with high-dose IL-2 classically administered together with TILs are severe and recent data have questioned its use tleurukzew (qzpicufbkf )
Positive
12 Mar 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free